111 related articles for article (PubMed ID: 15251087)
1. Statins prevent strokes in high-risk patients.
J Fam Pract; 2004 Jul; 53(7):522. PubMed ID: 15251087
[No Abstract] [Full Text] [Related]
2. [What has changed in therapy of vascular patients (role of statins and beta-adrenoblockers)].
Pokrovskiĭ AV; Goloviuk AL
Angiol Sosud Khir; 2010; 16(2):7-11. PubMed ID: 21032867
[TBL] [Abstract][Full Text] [Related]
3. Statins for high-risk patients without heart disease or high cholesterol.
Med Lett Drugs Ther; 2006 Jan; 48(1225):1-3. PubMed ID: 16374400
[No Abstract] [Full Text] [Related]
4. Clinical inquiries. Do statins reduce the risk of stroke?
Busch N; Kelsberg G; Kendall SK; Krist A
J Fam Pract; 2004 Jul; 53(7):575-7. PubMed ID: 15251101
[No Abstract] [Full Text] [Related]
5. Heart protection study finds simvastatin reduces vascular risk in a wide range of high-risk patients.
Collins R
Am J Manag Care; 2002 Jan; Suppl():6. PubMed ID: 11833455
[No Abstract] [Full Text] [Related]
6. Statins for asymptomatic middle cerebral artery stenosis: The Regression of Cerebral Artery Stenosis study.
Mok VC; Lam WW; Chen XY; Wong A; Ng PW; Tsoi TH; Yeung V; Liu R; Soo Y; Leung TW; Wong KS
Cerebrovasc Dis; 2009; 28(1):18-25. PubMed ID: 19420918
[TBL] [Abstract][Full Text] [Related]
7. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin.
Schick BA; Laaksonen R; Frohlich JJ; Päivä H; Lehtimäki T; Humphries KH; Côté HC
Clin Pharmacol Ther; 2007 May; 81(5):650-3. PubMed ID: 17329991
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events.
Michelena HI; Osorio LA; Citkowitz E
Int J Cardiol; 2005 May; 101(1):111-4. PubMed ID: 15860392
[TBL] [Abstract][Full Text] [Related]
9. Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing.
Patil S; Holt G; Raby N; McLellan AR; Smith K; O'Kane S; Beastall G; Crossan JF
J Orthop Res; 2009 Mar; 27(3):281-5. PubMed ID: 18853428
[TBL] [Abstract][Full Text] [Related]
10. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
Chonchol M; Cook T; Kjekshus J; Pedersen TR; Lindenfeld J
Am J Kidney Dis; 2007 Mar; 49(3):373-82. PubMed ID: 17336698
[TBL] [Abstract][Full Text] [Related]
11. Reduction of myocardial ischemia with simvastatin in addition to conventional treatment in patients with chronic coronary artery disease.
Verri V; Cunha AB; Tessarolo LE; Carneiro RC; Romêo Filho LJ
Rev Port Cardiol; 2004 Sep; 23(9):1089-105. PubMed ID: 15587571
[TBL] [Abstract][Full Text] [Related]
12. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
[TBL] [Abstract][Full Text] [Related]
13. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
14. Effect of 80 mg/day simvastatin therapy on cardiovascular outcomes in adults with versus without metabolic syndrome.
Kamalesh M; Rao R; Sawada S; Friend A; Schellhase E; Evans T
Am J Cardiol; 2006 May; 97(10):1487-9. PubMed ID: 16679089
[TBL] [Abstract][Full Text] [Related]
15. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
Päivä H; Thelen KM; Van Coster R; Smet J; De Paepe B; Mattila KM; Laakso J; Lehtimäki T; von Bergmann K; Lütjohann D; Laaksonen R
Clin Pharmacol Ther; 2005 Jul; 78(1):60-8. PubMed ID: 16003294
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin for cardiovascular prevention: too many uncertainties.
Prescrire Int; 2009 Aug; 18(102):176. PubMed ID: 19746571
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
18. Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus.
Hernandez TL; Capell WH; Wolfe P; Gerard LA; Eckel RH
Am J Cardiol; 2006 Dec; 98(12):1656-9. PubMed ID: 17145229
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
